key: cord-1012392-g7xl703p
authors: Downes, Damien J.; Cross, Amy R.; Hua, Peng; Roberts, Nigel; Schwessinger, Ron; Cutler, Antony J.; Munis, Altar M.; Brown, Jill; Mielczarek, Olga; de Andrea, Carlos E.; Melero, Ignacio; Gill, Deborah R.; Hyde, Stephen C.; Knight, Julian C.; Todd, John A.; Sansom, Stephen N.; Issa, Fadi; Davies, James O.J.; Hughes, Jim R.
title: Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
date: 2021-11-01
journal: Nat Genet
DOI: 10.1038/s41588-021-00955-3
sha: d39eab26fc4c95f604deb8072395f783e693cd32
doc_id: 1012392
cord_uid: g7xl703p

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic has caused millions of deaths worldwide. Genome-wide association studies (GWAS) identified the 3p21.31 region as conferring a two-fold increased risk of respiratory failure. Here, using a combined multiomics and machine-learning approach, we identify the gain-of-function risk A allele of a single-nucleotide polymorphism (SNP), rs17713054G>A, as a probable causative variant. We show with chromosome conformation capture and gene expression analysis that the rs17713054-affected enhancer upregulates the interacting gene, Leucine Zipper Transcription Factor Like 1 (LZTFL1). Selective spatial transcriptomic analysis of COVID-19 patient lung biopsies shows the presence of signals associated with epithelial-mesenchymal transition (EMT), a viral response pathway that is regulated by LZTFL1. We conclude that pulmonary epithelial cells undergoing EMT, rather than immune cells, are likely to be responsible for the 3p21.31 associated risk. As the 3p21.31 effect is conferred by a gain-of-function, LZTFL1 may provide a therapeutic target.

The COVID-19 pandemic is estimated to have caused over 4.6 million deaths so far 1, 2 . The predominant cause of mortality is pneumonia and severe acute respiratory distress syndrome 3 . However, COVID-19 can cause multiple organ failure through cytokine release, microvascular and macrovascular thrombosis, endothelial damage, acute kidney injury and myocarditis [4] [5] [6] . GWAS are important for identifying candidate genes and pathways that predispose to complex diseases 7 and genetically validated drug targets are more likely to lead to approved drugs 8 . Two large GWAS have been carried out to determine whether common variants drive susceptibility to severe COVID-19 9, 10 . Both studies identified a region of chromosome 3p21.31 as having the strongest association, whilst a third study also identified this locus as conferring susceptibility to infection 11 . The 3p21.31 risk haplotype, which arises from Neanderthal DNA 12 and is currently unexplained with regards to the causal variant(s), causal gene(s) and specific role in COVID-19, confers a two-fold increased risk of respiratory failure from COVID-19 9, 10 , and an over two-fold increased risk of mortality for under 60 year-olds 13 . Additionally, the risk variants at this locus are carried by >60% of individuals with South Asian ancestries (SAS), compared to 15% of white European ancestry (EUR) groups, partially explaining the ongoing higher death rate in this population in the United Kingdom 14, 15 .

Identifying the causal gene(s) and mechanism(s) behind GWAS hits poses several challenges. First, a causative variant is usually in linkage disequilibrium (LD) with many other variants and these can take different forms (SNPs, insertions, deletions and structural polymorphisms). Secondly, the genetic signals are completely cell-type agnostic, which makes it challenging to identify appropriate experimental models for further investigation. Thirdly, there are multiple mechanisms by which variants can have an effect. Alteration of the protein coding sequence or RNA splicing, both of which are relatively straightforward to disentangle, account for fewer than 20% of associations in polygenic disease 16 . The remaining variants and their target gene(s) can be very difficult to decode. Many are thought to lie within cis-regulatory elements 17 , such as enhancers, which are short DNA sequences that often control tissue-and developmental-stage-specific gene expression. Deciphering the variants that affect enhancers is challenging because many enhancers are only active in specific cell types or at specific times, enhancers are often distant in the linear DNA sequence (often 10 4 -10 6 bp) from the genes they control, and the effects of sequence changes are not straightforward to predict.

We have developed a comprehensive platform for decoding the effects of sequence variation identified by GWAS 16 (Extended Data Fig. 1a ). This combines computational and "wet lab" approaches to delineate the identity of causative variants, cell types involved and effector genes. Initially, GWAS-identified haplotypes are screened for potential protein coding sequence variants. Variants altering splice sites are then assessed using a combination of machine learning 18 and RNA-seq analysis. Conventional genomic approaches are then combined with machine learning 19 to define whether variants lie within, and affect, cis-regulatory sequences from a panel of disease relevant cell types; this allows for gene promoters, which physically contact the candidate enhancer sequence in the relevant cell type(s), and these data are integrated with gene expression analyses. Finally, genome editing is used to validate regulatory effects of prioritized variants.

Here, we have applied this approach to identify rs17713054 as a probable causative variant and LZTFL1 as a candidate effector gene in pulmonary epithelial cells as contributing to the strong COVID-19 association at the 3p21.31 locus; with EMT identified as a relevant infection response pathway.

The 3p21.31 region contains variants associated with the autoimmune diseases type-1 diabetes 23 and multiple sclerosis 24 , though the lead and tag variants identified in these studies are not in high LD with those associated with COVID-19 severity (Extended Data Fig. 1b ). There are 28 candidate risk variants in LD with the original genome-wide significant SNPs 9 at 3p21.31 (r 2 > 0.8, EUR; Extended Data Fig. 1c ). None of these variants affect coding sequences. One SNP, rs35624553 is in the 3' UTR of the gene LZTFL1 ( Fig. 1 ), but this is not a conserved miRNA binding site 25 and neither miRdSNP 26 nor MicroSNiPer 27 predict the variant alters miRNA binding. Four other variants are within LZTFL1 introns, including the lead SNP rs11385942 9 . None of these are predicted to alter mRNA splicing of LZTFL1, either by machine learning with SpliceAI 18 or splicing quantitative trait loci (sQTL) based approaches 28 , and the nearest exon junction to these variants is ~500 bp (Fig. 1) . Therefore, a cis-regulatory mechanism seems to be the most likely explanation for this haplotype.

We first examined open chromatin from 24 diverse immune cell populations 29 (including T, B, Natural Killer and dendritic cells) in resting and stimulated states, but did not identify any of the 28 severe COVID-19 associated variants at 3p21.31 in open chromatin (Extended Data Fig. 1d ); making it unlikely that a cis-regulatory mechanism in these immune cell types is responsible. By considering open-chromatin data from 95 diverse cell types we identified two SNPs, rs17713054 and rs76374459, which lie in open chromatin 30 (Fig. 1 , Extended Data Fig. 2 ). Machine-learning approaches have proven accurate at predicting allele-specific changes in transcription factor binding and chromatin accessibility 31,32 , including for de novo gain-of-function changes 33 . We have previously developed a machine-learning model, deepHaem 19 , which uses 694 DNase I hypersensitivity and ATAC-seq datasets to predict changes to active regulatory elements. Importantly, deepHaem predicted that the 26 variants not in open chromatin have no strong gain-of-function effect in any cell type (Extended Data Fig. 3 ).

Of the two variants in open chromatin, rs76374459 is unlikely to be causative. It is not contained within the Vindija Neanderthal risk haplotype 12 and is not in tight LD with the 3p21.31 lead SNPs from either of two GWAS 9,10 (rs11385942 r 2 = 0.737/0.058, EUR/ SAS; rs73064425 r 2 = 0.747/0.058, EUR/SAS). In addition, it is in an erythroid-specific enhancer, a cell-type not strongly implicated in SARS-CoV-2 infection, and it is not predicted by machine learning to cause damaging effects (Fig. 1 , Extended Data Figs. 2,4).

In contrast, rs17713054 is likely to be a causative SNP as it is in tight LD with both lead SNPs (rs11385942 r 2 = 1.0/1.0, EUR/SAS; rs73064425 r 2 = 0.986/0.995, EUR/SAS), is located in open chromatin in numerous COVID-19-relevant cell types including epithelial and endothelial cells (Fig. 1, Extended Data Fig. 2) , where it is marked by epigenetic modifications associated with active enhancers (histone H3 lysine-4 monomethylation [H3K4me1] and histone H3 lysine-27 acetylation [H3K27ac]). Inspection of single-cell ATAC-seq from healthy lung 34, 35 shows this enhancer is present in several lung epithelial cell types, including the ciliated epithelia and club cells, which line the respiratory tract, and in Type I and Type II pneumocytes, which form the alveoli (Fig. 1, Extended Data  Fig. 5 ). Interestingly, deepHaem predicts the rs17713054 risk allele, which is the minor allele A (MAF: 0.0817 EUR, 0.377 SAS 36 ), acts as a gain-of-function by augmenting an existing enhancer; resulting in increased chromatin accessibility in both epithelial and endothelial cells, and particularly in primary lung tissue (Fig. 2a) . Analysis of ATAC-seq for human aortic endothelial cells (HAECs) from 48 individuals 37 showed that the rs17713054 containing enhancer was significantly more accessible in heterozygous A/G donors than homozygous G/G donors (Fig. 2b) , and, in heterozygous samples, more reads originated the risk A allele than the non-risk G allele (Fig. 2c ).

Sequence analysis shows that the risk allele generates a second CCAAT/enhancer binding protein beta (CEBPB) motif 38 in the enhancer (Fig. 2d) . The biological relevance of this new motif is supported by strong expression of CEBPB in lung tissue 28 , and ChIP seq of CEBPB in HeLa, A549 alveolar basal epithelial adenocarcinoma, and IMR-90 lung fibroblast cells 39 -which are homozygous G/G non-risk -shows weak binding at the enhancer (Extended Data Fig. 6a-d) . Furthermore, deepHaem predicts rs17713054-A leads to increased CEBPB binding in IMR-90 and A549 cells (Extended Data Fig. 6e ). An orthogonal DNase I hypersensitivity footprinting based approach, Sasquatch 40 , uses genome-wide, cell-type-specific motif footprints to predict how sequence-specific changes alter transcription factor binding. This found that motifs containing either allele have strong DNase I footprints. When comparing motifs with the risk-A allele with the non-risk G allele, risk-A motifs showed a weak gain in accessibility in fetal lung and IMR-90 lung fibroblast cells (Fig. 2e) , corroborating a gain-of-function mechanism.

The 3p21.31 locus is gene dense and contains several candidates that could potentially be involved in COVID-19 pathogenesis. These include three chemokine receptors: CCR9 (which encodes a lymphocyte-expressed C-C chemokine receptor 41 ); CXCR6 (which is associated with sarcoidosis and is a co-receptor for HIV 42, 43 ) and XCR1 (which encodes a X-C chemokine receptor). Transcriptome-wide association study (TWAS) analysis has also identified CCR2, CCR3 and FYCO1, which lie up to 500 kb away, as candidate effector genes for the 3p21.31 COVID-19 association 10 . In addition, there are the two nearest genes that are less well studied: SLC6A20 (the SIT1 imino acid transporter associated with glycinuria 44 ) and LZTFL1 (Leucine zipper transcription factor-like 1 45 To identify candidate target genes of the rs17713054 enhancer we performed NuTi Capture C 20,21 from the promoters of genes in surrounding regulatory domains (Methods) in primary human umbilical vein endothelial cells (HUVEC) in which the rs17713054 enhancer is accessible, as well as resting and stimulated primary CD4 + T-cells, primary CD14 + monocytes, CD71 + CD235 + erythroid cells, and embryonic stem cells (H1-hESCs), where the enhancer is not accessible. In all cell types tested, all 28 COVID-19-associated variants fell within a domain of interaction that contained only the promoters of LZTFL1, SLC6A20, and CCR9, and is delimited by convergent CTCF boundary motifs (Fig. 3a) . Within this domain, the promoters of both LZTFL1 and SLC6A20 interacted more strongly with the rs17713054 enhancer than CCR9 (Fig. 3b) . Reciprocal Capture-C from the rs17713054 enhancer also showed its interactions were primarily constrained to the same domain (Extended Data Fig. 7a) . Notably, inside this domain, several tissue-specific enhancers could be seen for immune, erythroid and endothelial cell types; altering the interaction profile of the ubiquitously accessible LZTFL1 promoter and indicating dynamic regulation ( Supplementary Fig. 1 ).

We went on to perform Micro Capture-C (MCC), a 3C method that provides higher resolution data than conventional approaches 22 , from the rs17713054 enhancer in endothelial cells. MCC in HUVECs delineated significant tissue-specific interaction with the LZTFL1 promoter and the nearest upstream boundary CTCF site but no other significant peaks of interactions with any of the other gene promoters in the region (Fig. 3c , Extended Data Fig. 7a ). Importantly, we did not find a peak of interaction with SLC6A20, likely because ENCODE datasets show that SLC6A20 carries Polycomb repression marks in endothelial (HUVEC) and fibroblast (NHLF) cells (Extended Data Fig. 7b) . Additionally, the LZTFL1 promoter is more consistently accessible in cells where rs17713054 is also accessible (Extended Data Fig. 7c,d) . Therefore, LZTFL1 seems to be the most likely direct regulatory target of the rs17713054-containing epithelial-endothelial-fibroblast enhancer.

Disease biology, deepHaem, TWAS analysis 10 and a Phenome-wide association study 11 (PheWAS) identified lung tissue and function as key for the 3p21.31 COVID-19 association. Analysis of whole-lung RNA-seq 28 showed that LZTFL1 is strongly expressed in the lung (Fig. 4a) , and single-cell RNA-seq 48 shows that LZTFL1 is present throughout the respiratory epithelium, but predominantly expressed in ciliated cells (Fig. 4b,c ). Of the other candidate genes identified here and elsewhere 10,49,50 (SLC6A20, CCR2, CCR3, CCR9, CXCR6, and FYCO1), only SLC6A20 and FYCO1 are consistently expressed in both lung bulk and single-cell RNA-seq datasets, though CCR2 and CXCR6 were found in bulk RNA-seq. FYCO1 was found in most cell types and SLC6A20 was restricted to Goblet cells and Alveolar Type II pneumocytes (Fig. 4 , Extended Data Fig. 8 ). Analysis using the Genotype-Tissue Expression 28 (GTEx) portal for expression quantitative trait loci (eQTLs) showed that the rs17713054-A risk-allele is associated with higher levels of expression in the lung of LZTFL1 and SLC6A20 but not the other genes (Fig. 4d , Extended Data 8).

Colocalization analysis 51 shows that these GWAS and eQTL associations are more likely as a result of a single variant (PP = 0.2657) than two distinct variants (PP = 0.0566).

CRISPR-Cas9 genome editing 52 allows the possibility to test the role of the rs17713054 enhancer in regulation of LZTFL1 and SLC6A20. As the enhancer shows accessibility in epithelial, endothelial, and mesenchymal cells (Extended Data Fig. 9a ) we used CRISPR Cas9 ribonucleoprotein editing to delete either a 108-bp or a 191-bp region at high efficiency (>70%) from H441 distal lung epithelial cells, adult blood outgrowth endothelial cells, HUVECs and IMR-90 lung fibroblast cells (Extended Data Fig. 9b -d, Supplementary Fig.  2 ). Using real-time qPCR we detected no-effect on LZTFL1 expression following enhancer deletion (Extended Data Fig. 9e ) -consistent with a report that CRISPRi in the 16HBE14obronchial epithelial cell line had no effect on nearby gene expression 50 . As SLC6A20 is Polycomb repressed in fibroblasts and endothelial cells it was undetectable by RT-qPCR.

To understand the unexpected result, we generated H3K27ac ChIP-seq in all four cell types (Extended Data Fig. 9f ,g). The rs17713054 enhancer lacked strong H3K27ac and is likely inactive; explaining the lack of effect seen by deletion. Therefore, a suitable cell model for testing the effects of rs17713054, particularly in the lung epithelium, is not currently available.

Given that the rs17713054 enhancer is present and LZTFL1 is expressed in lung epithelial cells; the respiratory epithelium is of particular interest for understanding the association at 3p21.31. EMT, a developmental pathway that allows terminally differentiated epithelial cells to de-differentiate and acquire mesenchymal identity, plays a key role in the innate immune response and is a consequence of lung inflammation, involved in both the development and resolution of pneumonitis [53] [54] [55] [56] . SARS-CoV-2 is known to induce EMT in both lung carcinoma cell lines and in the respiratory tract 57,58 and LZTFL1 is known to regulate EMT through Wnt/β-catenin, hedgehog and TGF-β signalling 59, 60 . In the context of malignancy, increased levels of LZTFL1 inhibits EMT, whereas decreased LZTFL1 promotes EMT 45, 59, 60 .

Defining EMT in complex tissues is challenging due to its diverse and dynamic nature, but can be achieved through a combined assessment of cellular reorganization, an abundance of fibroblasts (which are products of EMT), presence of EMT promoting signaling pathways and co-expression of epithelial and mesenchymal markers 61 . Consistent with work by others 62,63 , we saw widespread epithelial dysfunction and diffuse alveolar damage (DAD) with reorganization indicative of EMT evident in post-mortem biopsies of three COVID-19 patients. Dysfunction in ciliated airways included denudation, hyperplasia, and squamous metaplasia (Fig. 5a) . Features of DAD included pneumocyte hyperplasia, hyaline membrane deposition, immune inflammation, fine-and focal-fibrosis, and squamous metaplasia (Fig.  5b) . Between the areas of interstitial expansion and fibrotic foci, there was an accumulation of fibroblasts, generally absent from healthy lung tissue.

We previously generated selective spatial transcriptomics from 46 areas of post-mortem biopsies from critical COVID-19 patients covering a spectrum of alveolar injury 64 . To explore expression profiles of EMT relevant genes we used both a cell deconvolution approach 65 , to estimate cell abundance through gene transcripts, and a Weighted Gene Correlation Network Analysis 66 (WGCNA), to identify modules of co-regulated gene expression patterns that were assigned to cell-types or biological processes. As expected, epithelial marker genes (CDH1, EPCAM) were naturally associated with Alveolar Type I (AT1) and Type II (AT2) pneumocytes, as well as both of the Epithelial and Type II pneumocyte WGCNA modules (Fig 5c, Extended Data Fig. 10 ). However, AT1, was also positively associated with the hallmark EMT gene ACTA2 (α-smooth muscle actin; Hmisc rcorr asymptomatic P = 0.0014), as were both the AT2 and Epithelial modules (P = 0.0069 and 9.59 × 10 -9 respectively). These two modules were also positively associated with a second mesenchymal EMT marker gene, the receptor tyrosine kinase encoding AXL (P = 0.0002 and P = 0.0031). We next investigated EMT-associated transcription factors, finding SNAI1 (Snail Family Transcriptional Repressor 1) positively associated with the epithelial module (P = 0.0491) and AT1 cells (P = 0.0432), while fibroblasts associated with SNAI2 (P = 1.08 × 10 -6 ) and the fibroblast module associated with both SNAI2 (P = 1.54 × 10 -8 ) and ZEB2 (Zinc finger E-box-binding homeobox 2; P = 0.0144). Finally, we investigated the Wnt/β-catenin and TGF-β pathways, finding both pneumocyte subtypes (AT1, AT2) and both epithelial modules associated with TGF-β signaling receptor genes (TGFBR1 and TGFBR2) and WNT signaling genes which encode β-catenin and frizzled receptors (CTNNB1, FZD6 and FZD7). By contrast, neither CD8 + T-cells nor the cytotoxicity and T-cell module expressed epithelial or mesenchymal genes, but they did express TGFB1 (P = 0.0029 and P = 0.0005 respectively). The colocalized expression of mesenchymal genes with epithelial cells, along with expression of EMT transcription factors and associated signaling pathways is indicative of the EMT process, highlighting the relevance of this cellular reorganization pathway in COVID-19. The modulation of EMT by LZTFL1 may therefore be of relevance to the pathological outcome of COVID-19 infection.

We have applied a machine learning and molecular biology platform for decoding GWAS hits, and identified a relatively unstudied gene, LZTFL1, as a candidate causal gene potentially responsible for the two-fold increased risk of respiratory failure from COVID-19 associated with 3p21.31. The risk allele of the SNP, rs17713054-A, leads to increased transcription, through augmentation of an epithelial-endothelial-fibroblast enhancer, facilitated by addition of a second CEBPB binding motif.

MCC identified LZTFL1 as the only gene to specifically interact with the rs17713054 enhancer. However, it is possible LZTFL1 may not be the sole causal gene at 3p21.31. Two TWASs identified 11 candidate genes at this locus 10, 49 , including LZTFL1 and SLC6A20, but only these two genes have strong 3C contacts with the rs17713054 enhancer and lung eQTLs. TWASs are unable to differentiate between direct and indirect regulation 67 . The absence of a 3C interaction with COVID-19 severity associated variants suggests that there may be an indirect effect for the remainder of the genes; with the caveat that it is possible that a direct effect may occur in an untested cell type. Whilst the ultra-high resolution MCC approach only identified physical contacts between LZTFL1 and rs17713054; traditional 3C found both CCR9 and SLC6A20 to be in the same regulatory domain. CCR9 is not expressed in lung and rs17713054 is not in an active enhancer in immune cells, where CCR9 is expressed. Both LZTFL1 and SLC6A20 have higher expression in the presence of the rs17713054 risk-allele, and it is plausible that in cells where SLC6A20 is not Polycomb repressed (e.g. Goblet and Alveolar Type II pneumocytes) it also directly interacts with the rs17713054 enhancer and would thus be affected by the risk allele.

The biological relevance of SLC6A20 to COVID-19 is unclear. It is primarily expressed in the kidneys and gastrointestinal tract, and its associated Mendelian disease causes renal calculi due to failure of reuptake of glycine in the nephron 44 . Nevertheless, its function as an imino acid transporter is modulated by levels of angiotensin-converting enzyme 2 68 (ACE2); which is a cell receptor for SARS-CoV-2 69 . Conversely, LZTFL1 is widely expressed in pulmonary epithelial cells, including ciliated epithelial cells, which have been identified as one of the main cellular targets for SARS-CoV-2 infection 70 . Furthermore, homozygous loss of LZTFL1 causes a classical ciliopathy: Bardet-Biedl syndrome 46, 47 . The association of 3p21.31 variants with susceptibility to SARS-CoV-2 infection, as well as disease severity, highlights the importance of the respiratory epithelium for this locus 11 . LZTFL1 encodes a cytosolic leucine-zipper protein, which associates with the epithelial marker E-cadherin and is involved in the trafficking of numerous signaling molecules 45, [71] [72] [73] [74] . We note that upregulation of LZTFL1 in the context of malignancy inhibits EMT 45,59,60 , a pathway known to be part of both wound healing and immune responses [53] [54] [55] [56] .

Examination of post-mortem COVID-19 lung biopsies demonstrates widespread epithelial dysfunction with EMT signatures 62, 63 . Consistently, single-cell RNA-seq shows a reduction in total numbers of epithelial cells following infection 75 , with a lower epithelial composition correlating with a more rapid progression from symptom onset to death 76 . The samples analyzed here showed few areas of healthy tissue and it is possible that inflammation or Neutrophil Extracellular Traps, rather than direct viral infection, was driving this epithelial dysfunction 58 , and that LZTFL1 acts earlier in disease progression, contributing to poor structural resolution of inflammation. Expression profiling of nasal epithelia from COVID-19 patients has detected EMT signals in the upper respiratory tract 57 . Similarly, SARS-CoV-2 infection of both a reconstructed human bronchial epithelium model and Syrian hamster induced de-differentiation of airway ciliated cells 77 , highlighting the relevance of this pathway and cell-type. As such, an effect of the 3p21.31 locus in the early epithelial response may contribute to susceptibility to SARS-CoV-2 infection 11 . Although both influenza and SARS-CoV-2 have been shown to induce EMT 57,78 , its role in viral infection is not entirely clear. While chronic EMT leads to fibrosis and severe inflammation, acute EMT may be a beneficial response. In the context of viral infection, EMT leads to a reduction of two of the cell receptors of SARS-CoV-2: ACE2 and transmembrane serine protease 2 (TMPRSS2) 57, 79 . A reduction in these cell surface markers as a result of EMT could reduce viral load by decreasing infection efficiency and preventing severe disease. Conversely, EMT allows for epithelial cells to proliferate, repair damaged tissue and replace lost cells -which may be required to overcome severe disease.

For the 3p21.31 COVID-19 risk locus, higher risk is associated with increased expression of LZTFL1, a known EMT inhibitor. Higher levels of LZTFL1 may delay the positive effects of an acute EMT response, blocking a reduction in ACE2 and TMPRSS2 levels and/or through slowing EMT-driven tissue repair. Further investigation of the potential role of LZTFL1 and EMT in pulmonary pathogenesis is needed. Our findings suggest that a gain-of-function variant in an inducible enhancer, causing increased expression of LZTFL1 

Human ESC line H1 (H1-hESC [https://scicrunch.org/resolver/CVCL_97711; WA01 WiCell, RRID:CVCL_9771) was grown on Matrigel (Corning) coated plates in mTeSR1 medium (StemCell technologies). Cells were harvested as a single-cell suspension using Accutase (EDM Millipore); fixation were carried out in mTeSR1 medium. Primary neonatal Human Umbilical Vein Endothelial Cells (HUVEC; Lonza; CC-2517, Gibco; C0035C, PromoCell; C-12200) were expanded in endothelial cell growth medium (Sigma) up to five passages following the manufacturer's protocol. For passaging, HUVECs were grown to 60% confluence, washed with HBSS at room temperature and sub-cultured following light trypsination using Trypsin-EDTA (Sigma) at room temperature with trypsin inhibitor (Sigma) added upon rounding of the cells to achieve gentle release from the flask. HUVECs were fixed in RPMI supplemented with 10% FBS. For erythroid cells, CD34 + hematopoietic stem and progenitor cells were isolated from peripheral blood of two healthy males and one healthy female and differentiated ex vivo for 13 days as previously described 82 European-Americans (EUR) were downloaded from the GTEx portal 28 . Coloc 51 (v5.0.1) analysis of variants within 200 kb of the predicted causal variant (rs17713054) was implemented in R. Inputs of GWAS size (n = 3,795), GWAS case frequency (0.419), eQTL study size (n = 515), as well as association β, standard errors, minor allele frequencies, and z-scores were used in a sensitivity analysis 88 which showed a prior probability of co-localization (p12) of 1 × 10 -5 tested approximately equal prior probability of both H 3 (two distinct causal variants for the GWAS and eQTL trait) and H 4 (a single causal variant).

Gene promoters were selected for Capture-C using 10-kb resolution Hi-C data on the 3D Genome Browser 89 

For deletion of the rs17713054 enhancer, cells were transfected with 5 μg Alt-R SpCas9 nuclease V3 ribonucleoprotein (IDT) and 0.1 nmol each of two guide RNAs (Supplementary Table 4 ). All transfections were carried out with 1-2 × 10 5 cells in 20 μl reactions using a 4D-Nucleofector (Lonza); IMR-90 Fibroblast cells were electroporated using Amaxa Cell Line Nucleofector Kit V reagents (Lonza) with program CM-120, HUVECs and BOECs were electroporated using Amaxa P5 Primary Cell 4D Nucleofector X Kit S reagents (Lonza) with program CA-167, and H441 epithelial cells were electroporated using P3 Primary Cell 4D-Nucleofector X Kit S reagents (Lonza) with program EL-10. Cells were cultured for 24 hours in 2 ml antibiotic-free growth media in a single well of a 6-well plate before expansion in fully supplemented media. Bulk DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen), and the edited region (chr3:45,817,769-45,818,459; hg38) amplified using Platinum PCR Supermix (Invitrogen) with 5'-GGAAAGAACACGCATAAACCATA-3' (Forward primer) and 5'-CTCATCCCACAGTGAACTAAGAA-3' (Reverse primer). Editing efficiency was determined using a D1000 Tapestation, and Sanger Sequencing with the forward primer and Synthego ICE analysis [https://ice.synthego.com/#/].

For expression analysis, cells were grown to >80% confluence in a single well of a 6-well plate. Cells were lysed by addition of 1 ml TRI Reagent (Sigma), snap frozen and stored at -80°C for less than 6 months. RNA was separated by addition of 100 μl of 1-bromo-3-chloropropane, centrifugation in a Phase Lock Gel-Heavy tube (5Prime) for 5 Europe PMC Funders Author Manuscripts minutes at 10,000 ×g, and precipitation in an equal volume of isopropanol (500 μl) with 1 μl of GlycoBlue (Thermo Fisher). DNA was removed using DNA-free DNA Removal Kit (Invitrogen) and cDNA generated using 1 μg of total RNA with SuperScript III First Strand Synthesis SuperMix reagents (Thermo Fisher). Quantitative PCR was performed using a 1:10 dilution of cDNA, TaqMan Universal PCR Master Mix II without UNG (Thermo Fisher) and TaqMan Gene Expression Assays (Thermo Fisher) for LZTFL1 (Hs00947898_m1), SLC6A20 (Hs00610960_m1) and RPL18 (Hs00965812_g1) with FAM. LZTFL1 expression was normalized to RPL18 and relative expression calculated by normalizing to the mean expression of LZTFL1 in RNP treated cells from samples of the same cell type processed in the same batch.

For ChIP, single-cell suspensions of 10 6 cells ml -1 in growth media were generated after light trypsin treatment. Cells were fixed by addition of 1% formaldehyde for 10 minutes at room temperature, which was quenched by addition of glycine at a final concentration of 125 mM. Fixed cells were washed with PBS and snap frozen. Cell lysis and immunoprecipitation was carried out using ChIP Assay Kit (Merk Millipore) on 5 × 10 6 cells in 2 ml of dilution buffer incubated overnight at 4°C with 1 μl polyclonal rabbit anti-H3K27ac (AbCam, ab4729, 0.3 μg, lot: GB3205523-I; 1:2,000). DNA was isolated by phenol-chloroform isoamylalcohol extraction and ethanol precipitation then indexed using NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB). Libraries were sequenced using 39-bp paired-end reads on a NextSeq Platform. Reads were mapped to hg38 using bowtie2 97 , PCR duplicates filtered using samtools 99 , and bigwigs generated with deeptools 100 . After the transposition DNA was extracted using MinElute PCR purification kit (Qiagen), half the DNA was amplified for sequencing using NEBNext High-Fidelity 2× PCR Master Mix (NEB) and further purified with QIAquick PCR purification kit (Qiagen). Libraries were sequenced using 39-bp paired-end reads on a NextSeq Platform. Reads were mapped to hg38 using bowtie2 in NGseqBasic 102 .

Cells were grown for 24-48 hours on sterilized coverslips under standard growth conditions and fixed in 4% vol/vol para-formaldehyde (PFA) in 0.25 M HEPES for 15 minutes, followed by permeabilization in 0.2% vol/vol Triton X-100 in PBS for 10 minutes. 

Healthy lung samples were sourced from chronic obstructive pulmonary disease (COPD) patients during lung tumor resection, with a sample of normal lung acquired away from the tumor. Medical records of COVID-19 patients were retrospectively reviewed 104 and three were selected for in-depth analysis based on: their clinical manifestation of acute respiratory distress syndrome (ARDS), typical COVID-19 histology (with a 4-5 score on the Brescia-COVID Respiratory Severity Scale), and a lung-restricted (absence in heart, liver and kidney biopsies) presence of SARS-CoV-2. Post-mortem lung tissues were obtained through open biopsy shortly after death and processed as fully described previosly 104 . In brief, tissues were immediately fixed in neutral buffered formalin for <24 hours and then paraffin embedded. Sections (5 μm each) were cut from Wedge biopsies (mean size 1.78 cm 2 , standard deviation 0.55 cm 2 ) for Hematoxylin and Eosin (H&E) analysis. Sections were analyzed by NanoString GeoMx Digital Spatial Profiling (DSP) with normalization and downstream analysis by weighted gene correlation network analysis 66 (WGCNA) and cell deconvolution 65 as previously described 64 . For deconvolution with SpatialDecon in R (v1.0.0), cell profiles were obtained from the Human Cell Atlas healthy lung single-cell RNA-seq appended with neutrophil data 105 using the R package dataset "Lung_plus_neut" dataset. Seven relevant cell types were selected for expression analysis from a total of 26 cell types. WGCNA was performed using the WGCNA R package (v1.70-3) and generated 17 biologically assignable modules, of which six were selected for further analysis. Spearman correlation and non-adjusted P value generation was performed with the Hmisc R package (v4.5-0) and visualized with corrplot (v0.84).

Unless stated, ENCODE datasets were accessed using the UCSC genome browser 106, 107 , which was also used to generate track figures. ENCODE DNase I bigwigs (hg38) were downloaded from ENCODE portal (https://www.encodeproject.org/) and analyzed with deeptools 100 (multiBigwigSummary). Capture-C was analyzed using the CaptureCompendium suite 91 mapping to hg38 with bowtie2 97 and using default settings. ATAC-seq and H3K27ac ChIP-seq data from erythroid progenitors, immune cells 29,80,81 and aortic endothelium 37 were downloaded from the Gene Expression Omnibus (GSE74912, GSE115684, GSE118189, GSE139377) and analyzed using NGseqBasic 102 with default settings for bowtie2 97 . Aortic endothelial samples were genotyped by counting two or more reads from either allele in combined ATAC-seq and ChIP-seq data. For allelic skew analysis, aortic endothelium ATAC-seq from heterozygous individuals was mapped with bowtie2 97 and processed using WASP 108 to correct for reference genome mapping bias. Three replicates with fewer than four remaining reads were excluded from analysis. Mature erythroid chromatin modification and CTCF data (GSE125926) have been previously reported by our group 16 , CTCF motifs were identified using MEME-SUITE 85 tools, (meme --dna --nmotifs 1 --w 19 --mod zoops --maxsize 1102788; fimo --thresh 1e-4 --motif 1). Single-cell RNA-seq data 35 No variants with r 2 >0.6 were seen beyond this range. d, Overlaid tracks of ATAC-seq from sorted populations of resting (blue) and stimulated (red) immune cells 29 . 

Refer to Web version on PubMed Central for supplementary material. a, DpnII Capture-C derived mean interaction count (n = 3 for all except CD14 + : n = 2) and one standard deviation (shading) for gene promoters in human vein endothelial cells (HUVEC), resting and activated T-Cells (CD4 + Non-Act/Act), monocytes (CD14 + ), CD235 + CD71 + erythroid cells and human embryonic stem cells (H1-hESCs). The enhancer containing rs17713054 is highlighted by a grey box. ATAC-seq/DNase I for each cell-type is shown underneath in black. CTCF track shows binding of the CCAAT-binding factor which acts as a boundary with forward and reverse motif orientation shown with arrowheads Per fragment interactions were smoothed using 250-bp bins and a 5-kb window. Solid line shows mean interaction count (n = 3 independent samples) with one standard deviation (shading). c, Micro Capture-C (MCC) of the rs17713054 enhancer in endothelial (HUVEC, blue) and erythroid (HUDEP-2, red) cells with tissue specific open chromatin tracks (n = 3). Peak analysis of MCC using LanceOtron to compare HUVEC and HUDEP-2 profiles identified two significantly enriched peaks in HUVEC cells (black triangles, P ≤ 1 × 10 -999 ) which correspond to the LZTFL1 promoter and the upstream CTCF site. Hematoxylin and eosin (H&E) stained biopsies of the ciliated respiratory epithelium on bronchiole (a) and of alveolar space (b) in healthy lung (i) and COVID-19 patient lung (ii iv). COVID-19 patient samples are representative images from staining of biopsies from 3 individuals and show loss of ciliated cell lined bronchioles (denudation) and loss of alveolar monolayers populated by alveolar type I pneumocytes with few type II pneumocytes, with alveolar wall expansion and fine interstitial fibrosis. Scale bars show 50 μM. c, Spearman correlation of gene expression profiles for EMT-related genes with the eigengenes of cell 

is funded by an MRC Clinician Scientist Award (MR/R008108) and received Wellcome support (098931/Z/12/Z). J.C.K. is a Wellcome Investigator (WT204969/Z/16/Z) and supported by NIHR Oxford Biomedical Research Centre and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS)

Conserved miRNA sites were identified on miRdSNP

A novel coronavirus from patients with pneumonia in China

An interactive web-based dashboard to track COVID-19 in real time

Bench-to-bedside review: Microvascular and airspace linkage in ventilator-induced lung injury

Coagulation abnormalities and thrombosis in patients with COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

10 Years of GWAS Discovery: Biology, Function, and Translation

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

Genomewide Association Study of Severe COVID-19 with Respiratory Failure

Genetic mechanisms of critical illness in Covid-19

Mapping the human genetic architecture of COVID-19

The major genetic risk factor for severe COVID-19 is inherited from Neanderthals

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England

ICNARC. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland

An integrated platform to systematically identify causal variants and genes for polygenic human traits

Potential etiologic and functional implications of genome-wide association loci for human diseases and traits

Predicting Splicing from Primary Sequence with Deep Learning

DeepC: predicting 3D genome folding using megabase-scale transfer learning

Multiplexed analysis of chromosome conformation at vastly improved sensitivity

High-resolution targeted 3C interrogation of cis-regulatory element organisation at genome-wide scale

Defining genome architecture at base-pair resolution

Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells,genes and drug targets for type 1 diabetes

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science (80-)

Predicting effective microRNA target sites in mammalian mRNAs

A database of disease-associated SNPs and microRNA target sites on 3'UTRs of human genes

MicroSNiPer: A web tool for prediction of SNP effects on putative microRNA targets

The GTEx Consortium atlas of genetic regulatory effects across human tissues

Landscape of stimulation-responsive chromatin across diverse human immune cells

The accessible chromatin landscape of the human genome

Basset: learning the regulatory code of the accessible genome with deep convolutional neural networks

Predicting effects of noncoding variants with deep learning-based sequence model

A gain-of-function single nucleotide variant creates a new promoter which acts as an orientation-dependent enhancer-blocker

A human cell atlas of fetal chromatin accessibility. Science (80-)

Single-cell multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of sars-cov2 host genes

Available at: www

Systems Genetics in Human Endothelial Cells Identifies Non-coding Variants Modifying Enhancers, Expression, and Complex Disease Traits

The CCAAT/enhancer binding protein (C/EBPα) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBPβ) gene (CEBPB) maps to human chromosome 20q13

An integrated encyclopedia of DNA elements in the human genome

Sasquatch: predicting the impact of regulatory SNPs on transcription factor binding from cell-and tissue-specific DNase footprints

A Role for CCR9 in T Lymphocyte Development and Migration

A Novel Chemokine Receptor-like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line-tropic HIV-1

Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis

Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters

Tumor-suppressive functions of leucine zipper transcription factor-like 1

Mechanistic insights into Bardet-Biedl syndrome, a model ciliopathy

Exome sequencing identifies mutations in LZTFL1, a bbsome and smoothened trafficking regulator, in a family with bardetebiedl syndrome with situs inversus and insertional polydactyly

A cellular census of human lungs identifies novel cell states in health and in asthma

Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization

Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19

Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics

RNA-Guided Human Genome Engineering via Cas9. Science (80-)

New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer

The basics of epithelial-mesenchymal transition

Molecular mechanisms of epithelial-mesenchymal transition

Epithelial-Mesenchymal Transitions in Development and Disease

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology

Neutrophil extracellular traps induce the epithelial-mesenchymal transition: implications in post-COVID-19 fibrosis. Front Immunol

LZTFL1 suppresses lung tumorigenesis by maintaining differentiation of lung epithelial cells

LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of P-catenin

Guidelines and definitions for research on epithelial-mesenchymal transition

Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients

COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City

Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune pathways related to tissue injury

Advances in mixed cell deconvolution enable quantification of cell types in spatially-resolved gene expression data

WGCNA: An R package for weighted correlation network analysis

Integrative approaches for large-scale transcriptome-wide association studies

Defective intestinal amino acid absorption in Ace2 null mice

Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors

Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes

Leucine zipper transcription factor-like 1 binds adaptor protein complex-1 and 2 and participates in trafficking of transferrin receptor 1

Regulation of Insulin Receptor Trafficking by Bardet Biedl Syndrome Proteins

Lztfl1/BBS17 controls energy homeostasis by regulating the leptin signaling in the hypothalamic neurons

A novel protein LZTFL1 regulates ciliary trafficking of the BBSome and smoothened

A molecular single-cell lung atlas of lethal COVID-19

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets

SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

H1N1 Influenza Virus Cross-Activates Gli1 to Disrupt the Intercellular Junctions of Alveolar Epithelial Cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution

Recapitulation of erythropoiesis in congenital dyserythropoietic anaemia type I (CDA-I) identifies defects in differentiation and nucleolar abnormalities

Establishment of outgrowth endothelial cells from peripheral blood

Establishment of Immortalized Human Erythroid Progenitor Cell Lines Able to Produce Enucleated Red Blood Cells

Suite: Tools for motif discovery and searching

Update of the open-Access database of transcription factor binding profiles

The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019

Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses

The 3D Genome Browser: A web-based browser for visualizing 3D genome organization and long-range chromatin interactions

Chromosome Conformation Capture with Nuclear Titrated Capture-C (NuTi Capture-C)

CaptureCompendium: a comprehensive toolkit for 3C analysis

FLASH: fast length adjustment of short reads to improve genome assemblies

BLAT---The BLAST-Like Alignment Tool

Fast gapped-read alignment with Bowtie 2

LanceOtron: a deep learning peak caller for ATAC-seq, ChIP-seq, and DNase-seq

The Sequence Alignment/Map format and SAMtools

deepTools2: a next generation web server for deep-sequencing data analysis

Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position

NGseqBasic -a single-command UNIX tool for ATAC-seq, DNaseI-seq, Cut-and-Run, and ChIP-seq data mapping, high-resolution visualisation, and quality control. bioRxiv

An open-source platform for biological-image analysis

Histopathological findings in fatal COVID-19 severe acute respiratory syndrome: Preliminary experience from a series of 10 Spanish patients

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

The Human Genome Browser at UCSC

ENCODE Data in the UCSC Genome Browser: year 5 update

WASP: Allele-specific software for robust molecular quantitative trait locus discovery

type modules identified by WGCNA analysis from spatially resolved expression data from COVID-19 patient lung. P values were identified by two-sided Hmisc analysis

Author manuscript; available in PMC

Europe PMC Funders Author Manuscripts Europe PMC Funders Author Manuscripts

We would like to thank Priscila Hirschfeld, Matt Gosden, Steph Carpenter, Caz Harrold, Lea Nussbaum, Yavor Bozhilov, Andrew King, Mohsin Badat, Minnie Salmon, Lance Hentges, Andrew Brown, Guiseppe Scozzafava, Alicia Lledó Lara, Tim Rostron, Jason Torres, Chris Eijsbouts, Valentina Iotchkova, and Martin Sergeant for their help with cell culture, experiments, and data analysis, Rob Beagrie for critical reading of the manuscript, and Doug Higgs for nurturing this research.

All custom analysis code and links to software are available on Github https://github.com/ Hughes-Genome-Group/Downes_2021_LZTFL1_Covid.git. Note, MCCsplitter.pl and